v3.25.2
Organization (Details) - USD ($)
$ / shares in Units, $ in Thousands
May 08, 2025
Apr. 25, 2025
Jun. 30, 2025
Dec. 31, 2024
Debt Instrument [Line Items]        
Cash and cash equivalents     $ 30,033 $ 22,036
Accumulated deficit     $ (302,522) $ (294,331)
2025 Public Offering        
Debt Instrument [Line Items]        
Sale of stock, number of shares issued in transaction (in shares) 3,852,500      
Sold, price per share $ 5.25      
Proceeds from public offering, net $ 18,600      
Tranche A Warrant Shares        
Debt Instrument [Line Items]        
Class of warrant or right, vested and exercisable (in shares)   400,000    
Amended Loan Agreement | Innovatus Life Sciences Lending Fund | Loan payable        
Debt Instrument [Line Items]        
Loan repayment   $ 19,700    
Perceptive Term Loan Facility | Warrant Certificate        
Debt Instrument [Line Items]        
Number of common shares to be called upon exercise of warrants (in shares)   1,150,000    
Perceptive Term Loan Facility | Tranche A Warrant Shares        
Debt Instrument [Line Items]        
Class of warrant or right, vested and exercisable (in shares)   400,000    
Perceptive Term Loan Facility | Credit Agreement Warrants        
Debt Instrument [Line Items]        
Class of warrant or right, vested and exercisable (in shares)   750,000    
Delayed Draw Term Loan | Tranche A Loan | Perceptive Credit Holdings IV, LP | Line of Credit        
Debt Instrument [Line Items]        
Proceeds from lines of credit   $ 25,000    
Delayed Draw Term Loan | Perceptive Term Loan Facility | Perceptive Credit Holdings IV, LP | Line of Credit        
Debt Instrument [Line Items]        
Proceeds from lines of credit   3,000    
Line of credit facility, maximum borrowing capacity   $ 75,000